Petrelintide does not have a dose. It has trial arms. This guide lays out every amount the sponsors have actually tested in people, shows what each one did, and flags what nobody has disclosed yet.
Ask PeptideBlog about any peptide
Quick answer: Petrelintide has no approved dose. The only published human amounts come from sponsor trials. Phase 2 ZUPREME-1 tested 1.0, 2.5, 5.0, 7.0 and 9.0 mg once weekly by subcutaneous injection for 42 weeks, with doses stepped up gradually.[1] Phase 1 tested single doses of 0.04 to 2.4 mg and weekly doses with targets up to 9.0 mg.[2] Phase 3 amounts are undisclosed. These are trial arms, not recommendations.
Figures in this section summarize amounts and schedules reported in published research or registered trials. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Every studied petrelintide amount at a glance
Here is the whole picture in one table. Each row is a trial arm run by the sponsors, with the evidence category in the last column.
Swipe the table sideways to see every column.
| Trial | Population | Route | Amount studied | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Phase 1, single ascending dose | Adults, normal weight or overweight | Subcutaneous; one intravenous arm | 0.04 to 2.4 mg subcutaneous; 0.35 mg intravenous | Single dose | One dose | Published human clinical trial[2] |
| Phase 1, multiple dose part 1 | Adults, normal weight or overweight | Subcutaneous | 0.6 mg and 1.2 mg | Once weekly | 6 doses | Published human clinical trial[2] |
| Phase 1, multiple dose part 2 | Adults with overweight or obesity | Subcutaneous | Escalated to targets of 2.4, 4.8 and 9.0 mg | Once weekly, stepped up every 2 weeks | 16 doses | Published human clinical trial[2] |
| ZUPREME-1 (phase 2) | Adults with obesity, no type 2 diabetes | Subcutaneous, self-administered | 1.0, 2.5, 5.0, 7.0 and 9.0 mg maintenance doses | Once weekly | 42 weeks including escalation | Published human clinical trial[1][3] |
| ZUPREME-2 (phase 2b) | Adults with overweight or obesity and type 2 diabetes | Subcutaneous (sponsor announcement) | Three doses; milligram amounts not disclosed | Once weekly | Primary endpoint at week 28 | Registered trial, company-reported topline[4][8] |
| ZUPREME-3 (phase 3) | Adults with overweight or obesity, no diabetes (3,900 planned) | Subcutaneous, drug-device combination product (registry) | Not disclosed; one petrelintide arm registered | Once weekly | Primary endpoint at week 64 | Registered human trial, ongoing[5] |
| ZUPREME-4 (phase 3) | Adults with overweight or obesity and type 2 diabetes (600 planned) | Subcutaneous, drug-device combination product (registry) | Not disclosed; one petrelintide arm registered | Once weekly | Primary endpoint at week 64 | Registered human trial, ongoing[6] |
| ZUPREME-5 (phase 3) | Adults 40+ with overweight or obesity and cardiovascular disease (2,500 planned) | Subcutaneous, drug-device combination product (registry) | Not disclosed; one petrelintide arm registered | Once weekly | Primary endpoint at week 64; primary completion July 2030 | Registered human trial, ongoing[7] |
| Any vendor, forum or community protocol | Not applicable | Not applicable | Not consistently reported | Not consistently reported | Not consistently reported | No established or reliably sourced dosing information was identified |
Phase 3 records show a once-weekly design in their titles and one petrelintide arm versus placebo. Sponsors have not posted the milligram amounts. Enrollment numbers are the registered targets, not completed enrollment.
Where these figures come from
Every milligram amount above traces to one of two peer-reviewed papers or to a registry record. That is rare for a peptide search term, so here is the plain version.
- Most-reported figure: the 1.0 to 9.0 mg weekly range, because it is the published phase 2 dose range.[1]
- Origin: Zealand Pharma’s own trial, reported in The Lancet Diabetes & Endocrinology on 29 September 2026. The authors include Zealand employees and the trial was funded by Zealand.[1]
- Human evidence: yes, for ZUPREME-1 and for Phase 1. Nothing for Phase 3 yet.[1][2]
- Animal evidence: none was used for this page, and nobody should convert animal amounts into a human one.
- Practitioner or community figures: none identified. No established or reliably sourced dosing information was identified outside the sponsors’ trials.
- Websites repeating each other: the main risk is copying of the 1.0 to 9.0 mg range with no source or with a vendor’s label attached. Count it once, and trace it to reference 1.
- Weight-based conversions: none are supported. All amounts here are fixed milligram doses, not milligrams per kilogram.
ZUPREME-1, dose by dose
ZUPREME-1 is the one trial that lets you compare petrelintide doses side by side. It enrolled 493 adults (485 received at least one dose) with obesity, or overweight plus high blood pressure or abnormal blood fats, and no type 2 diabetes. They were randomized 5 to 1 to one of five fixed weekly maintenance doses or placebo, and the primary endpoint was percent weight change at week 28.[1] The registry entry is on our ZUPREME-1 trial page.
Swipe the table sideways to see every column.
| Weekly dose | Participants dosed | Mean weight change (95% CI) | Difference vs placebo (95% CI) |
|---|---|---|---|
| 1.0 mg | 79 | -7.9% (-9.0 to -6.7) | -6.2% (-7.9 to -4.5) |
| 2.5 mg | 81 | -7.9% (-9.0 to -6.7) | -6.2% (-7.8 to -4.5) |
| 5.0 mg | 83 | -9.8% (-10.9 to -8.6) | -8.1% (-9.7 to -6.5) |
| 7.0 mg | 79 | -9.3% (-10.5 to -8.2) | -7.7% (-9.3 to -6.0) |
| 9.0 mg | 82 | -9.4% (-10.5 to -8.3) | -7.7% (-9.4 to -6.1) |
| Placebo | 81 | -1.7% (-2.8 to -0.5) | not applicable |
Source: published abstract.[1] The efficacy estimand describes results as if participants had stayed on treatment, so it is more favorable than an analysis that counts everyone as randomized. Missing data were assumed to be missing at random.
What the dose response actually shows
The tempting read is “more milligrams, more weight loss.” The data do not say that. Going from 1.0 to 5.0 mg lifted mean loss from 7.9% to 9.8%. Going from 5.0 to 9.0 mg did not lift it further (9.4%), and the 7.0 mg arm sat in between at 9.3%.[1] Every 95% confidence interval for the three highest arms overlaps the others, and each arm had only about 80 people, so small gaps between arms are not reliable.
Two other points from the paper. Weight kept falling after the primary endpoint, with reductions of up to 10.7% by week 42.[1] And tolerability was mostly a nausea story: 79 of 404 petrelintide participants (20%) versus 5 of 81 on placebo (6%), with vomiting at 3% versus 6%, diarrhea at 7% versus 7% and constipation at 7% versus 4%.[1] The abstract does not break side effects out by dose, so it cannot tell you whether the 9.0 mg arm felt different from the 1.0 mg arm.
For the full efficacy and safety picture, see our petrelintide, eloralintide and cagrilintide comparison and the petrelintide research entry.
Phase 1: the first human doses
Before ZUPREME-1, Zealand ran two randomized, placebo-controlled Phase 1 trials. The single ascending dose trial tested subcutaneous doses from 0.04 to 2.4 mg plus one 0.35 mg intravenous dose. The multiple ascending dose trial gave six weekly doses of 0.6 and 1.2 mg in part 1, then 16 weekly doses in part 2 that were stepped up every 2 weeks to target doses of 2.4, 4.8 and 9.0 mg.[2]
The top Phase 1 target, 9.0 mg, is the same number as the highest ZUPREME-1 arm, which is how the two trials connect. Part 2 produced weight loss of up to 8.6% after 16 weeks. Petrelintide was slowly absorbed, had a half-life of about 10 days, and showed steady-state dose proportionality, meaning exposure rose in step with dose.[2] In plain English, the drug lingers in the body for well over a week, which fits a once-weekly schedule.
No serious or severe adverse events were reported. Nausea occurred in 16.7% to 33.3% of petrelintide participants versus 16.7% on placebo in part 2, diarrhea was rare, and vomiting happened only in the one participant who stopped treatment for GI reasons.[2] These are small Phase 1 groups, so treat the percentages as rough.
Dose escalation and weekly timing
The longer petrelintide trials phase in the dose rather than starting at the maintenance amount. The ZUPREME-1 authors describe the nausea as predominantly mild and occurring during dose escalation.[1]
Swipe the table sideways to see every column.
| Trial | Escalation reported | Source |
|---|---|---|
| Phase 1 MAD part 2 | 16 weekly doses, increased every 2 weeks to target doses of 2.4, 4.8 and 9.0 mg | Published trial[2] |
| ZUPREME-1 | 42 weeks “including dose escalation.” The sponsor’s ADA 2026 poster says doses were stepped up every 4 weeks, with escalation lasting 4 to 16 weeks. The step size has not been published. | Published trial[1]; sponsor poster[9] |
| ZUPREME-2 | Up to 16 weeks of escalation with a step every fourth week, then maintenance until week 28 | Sponsor announcement[8] |
| ZUPREME-3, -4 and -5 | Escalation schedule not stated in the registry records. Each registers one petrelintide arm versus placebo. | Registry[5][6][7] |
Dose-escalation details beyond what the papers state are not asserted here. No one should infer a starting dose or step size for petrelintide from this page.
A note on timing. Everything above is once weekly. The registry and papers do not report a preferred day, time of day, or relation to meals, and nothing here should be read as one.[1][3] If you want the unit logic behind weekly schedules in general, our reconstitution calculator shows the math for any vial size, liquid volume and amount you type in, with no preset values. It cannot tell you anything about petrelintide, because no concentration for trial supply has been published.
ZUPREME-2 and the Phase 3 program
ZUPREME-2 tested three petrelintide doses against placebo in 221 adults with overweight or obesity and type 2 diabetes on metformin, with or without an SGLT2 inhibitor. The registry lists it as completed on 13 August 2026 with a week 28 primary endpoint.[4] See the ZUPREME-2 trial page. Zealand reported topline results on 7 October 2026, describing three once-weekly subcutaneous doses with escalation every fourth week for up to 16 weeks and maintenance until week 28, without giving the milligram amount of any arm.[8] Until the full data appear, ZUPREME-2 tells you nothing about specific amounts.
The Phase 3 ZUPREME program started on 30 September 2026 with three trials sponsored by Roche and measuring percent weight change at week 64: ZUPREME-3 (3,900 planned, no diabetes, primary completion December 2028), ZUPREME-4 (600 planned, with type 2 diabetes, October 2028) and ZUPREME-5 (2,500 planned, established cardiovascular disease, July 2030).[5][6][7] None lists a milligram dose. Each registers a single petrelintide arm against placebo, given subcutaneously with a drug-device combination product. Follow the clinical trial tracker for status changes.
What is not public
- The Phase 3 dose or doses, and whether one or several will be tested.
- The ZUPREME-2 arm amounts and the per-dose side-effect rates from ZUPREME-1.
- The step-by-step escalation schedules.
- The concentration or formulation of trial supply, which is why a mg-to-units conversion would be a guess.
- Any dose-response data beyond 9.0 mg weekly.
- Whether a lower dose such as 1.0 or 2.5 mg would hold weight loss long term.
- Any direct comparison with other amylin drugs at matched doses. See eloralintide and cagrilintide for what each has published on its own. Eloralintide Research sets the two trial programs side by side in its petrelintide vs eloralintide comparison.
Products, listings and trial data
Petrelintide is not an approved medicine and not a pharmacy product. Some research suppliers have begun listing it for laboratory use. A supplier listing is not the sponsor’s trial drug, has not been reviewed by a regulator, and none of the figures on this page transfer to it. For readers tracking supplier availability, there is one coming-soon research listing. Nothing about it implies a dose.
Frequently asked questions
What dosage of petrelintide has been studied?
In the published phase 2 trial ZUPREME-1, adults received once-weekly subcutaneous petrelintide at maintenance doses of 1.0, 2.5, 5.0, 7.0 or 9.0 mg, or placebo, for 42 weeks including dose escalation. Phase 1 trials tested single doses of 0.04 to 2.4 mg and weekly doses with targets up to 9.0 mg. These are trial arms, not recommended amounts.
What is the standard petrelintide dose?
There is no standard dose. Petrelintide is not approved, so no label dose exists. The Phase 3 trials have not disclosed which amount or amounts they use.
Which petrelintide dose gave the most weight loss?
At the week 28 primary endpoint of ZUPREME-1, the 5.0 mg arm had the largest mean loss, 9.8%, versus 9.3% at 7.0 mg and 9.4% at 9.0 mg. The confidence intervals overlap, so the trial does not show that any one of the top three arms beat the others.
How often is petrelintide dosed?
Once weekly in every registered human trial reviewed. Phase 1 data showed a half-life of about 10 days, which is consistent with weekly dosing.
How is petrelintide given in trials?
By subcutaneous injection. In ZUPREME-1 participants self-administered using a vial and syringe, according to the trial registry. Phase 1 also tested a single intravenous dose of 0.35 mg.
Do doses start low and increase?
Yes. ZUPREME-1 ran 42 weeks including dose escalation, and the Phase 1 multiple-dose trial stepped up every 2 weeks to its target. Nausea in ZUPREME-1 was mostly mild and occurred during escalation.
Is there a community or online petrelintide protocol?
No established or reliably sourced dosing information was identified outside the sponsors’ own trials. Figures that appear elsewhere online should be traced to the trial records listed on this page.
Can you buy petrelintide?
Not as an approved medicine. Petrelintide has no approval anywhere. Some research suppliers list it for laboratory use, including this coming-soon research listing. Such products are not the sponsor’s trial drug and are not covered by any trial data.
How long do the Phase 3 trials last?
ZUPREME-3 and ZUPREME-4 measure weight change at week 64, with primary completion registered for December 2028 and October 2028. ZUPREME-5, in people with cardiovascular disease, lists primary completion in July 2030.
Bottom line
Almost everything known about petrelintide amounts comes from one company’s trials. What is genuinely published: single doses of 0.04 to 2.4 mg and weekly doses with targets to 9.0 mg in Phase 1,[2] and 1.0 to 9.0 mg weekly in ZUPREME-1.[1] What is merely reported: ZUPREME-2 topline results with no amounts. What is speculative: any claim about the best dose, which the data do not settle, since 5.0, 7.0 and 9.0 mg performed alike. What is missing: Phase 3 doses, long-term results, and a regulatory filing. Petrelintide is in Phase 3 and approved nowhere.
Keep reading
Sources
- Garvey WT, Ard J, Connery L, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14(11):914-926. Published 29 September 2026. https://doi.org/10.1016/S2213-8587(26)00213-5 Published human clinical trial (Tier 1). Funded by Zealand Pharma. PMID 42810355.
- Braendholt Olsen M, Griffin J, Hovelmann U, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management: two randomized, controlled phase 1 trials. Diabetes Obes Metab. 2026;28(7):5915-5925. Published 22 April 2026. https://doi.org/10.1111/dom.70753 Published human clinical trial (Tier 1). Authors from Zealand Pharma and Profil. PMID 42017294, PMC13243934.
- ClinicalTrials.gov. NCT06662539: Once-weekly petrelintide versus placebo for obesity or overweight with co-morbidities (ZUPREME-1). Sponsor: Zealand Pharma. https://clinicaltrials.gov/study/NCT06662539 Trial registry record. Registered human trial (Tier 2 as a record; results are in reference 1).
- ClinicalTrials.gov. NCT06926842: Efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes (ZUPREME-2). Sponsor: Zealand Pharma. https://clinicaltrials.gov/study/NCT06926842 Trial registry record. Completed; no results posted at the registry.
- ClinicalTrials.gov. NCT07843498: Phase III petrelintide in overweight or obesity (ZUPREME-3). Sponsor: Hoffmann-La Roche; collaborator Zealand Pharma. https://clinicaltrials.gov/study/NCT07843498 Trial registry record. Recruiting; no results.
- ClinicalTrials.gov. NCT07843485: Phase III petrelintide in overweight or obesity and type 2 diabetes (ZUPREME-4). Sponsor: Hoffmann-La Roche. https://clinicaltrials.gov/study/NCT07843485 Trial registry record. Recruiting; no results.
- ClinicalTrials.gov. NCT07843472: Phase III petrelintide in overweight or obesity and established cardiovascular disease (ZUPREME-5). Sponsor: Hoffmann-La Roche. https://clinicaltrials.gov/study/NCT07843472 Trial registry record. Recruiting; no results.
- Zealand Pharma. Company announcement No. 54 / 2026: positive phase 2 ZUPREME-2 topline results for petrelintide in people with overweight or obesity and type 2 diabetes. 7 October 2026 (copy distributed by Inderes). https://www.inderes.fi/releases/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes Company announcement (sponsor-reported, not peer reviewed).
- Garvey WT, et al. ZUPREME-1 poster and slides, American Diabetes Association Scientific Sessions 2026. Zealand Pharma. https://www.zealandpharma.com/media/4lzjvdba/garvey-et-al_zupreme1_ada2026_poster_and_slides.pdf Sponsor conference poster (developer document), not peer reviewed. Used for the escalation schedule.
Educational reference only, not medical advice. This page documents amounts studied in published and registered research. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.
